Trastuzumab

Quiénes somos

  • 5 de abril de 2022
    The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
  • 5 de abril de 2022
    S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
  • 5 de abril de 2022
    Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
  • 5 de abril de 2022
    A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)